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Abstract An increasing number of patients with colo-
rectal cancer (CRC) receive genetic counselling within
1 year after diagnosis. Little is known whether speciﬁc
subgroups are more vulnerable for genetic testing related
distress. A literature review was conducted to identify the
psychological impact of CRC in the ﬁrst year, and the
additional impact of genetic testing. The electronic dat-
abases of PubMed, PsychInfo, Embase and the Cochrane
Library were searched to identify all reports published
between January 1997 and October 2007 on the psycho-
logical impact of (1) CRC-diagnosis up to 1 year after
treatment and of (2) genetic testing for Lynch syndrome in
patients with CRC. Studies on the psychological impact of
genetic testing in newly diagnosed patient with CRC were
not available. Either CRC patients diagnosed several years
ago were studied and the focus was also often on the
psychological impact of genetic testing prior to DNA-test
disclosure. They show that limitations in emotional and
social functioning can persist up to 1 year after CRC
treatment, especially in those with a stoma or diagnosed
before age 60. Female patients and male patients diagnosed
before age 50 appear to be more vulnerable to genetic test-
related distress. It is well known that being treated for CRC
has great impact on psychological functioning. Little is
known about the psychological impact during the ﬁrst year
after diagnosis and very little is known about the additional
psychological effect of genetic testing for hereditary cancer
in this period. We found presumptive evidence that speciﬁc
subgroups of patients with CRC are more vulnerable for
genetic-testing-related distress.
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Introduction
Up to 5% of patients with colorectal cancer have Lynch
syndrome (hereditary non-polyposis colorectal cancer
(HNPCC) [1–3]. Unfortunately, only a small proportion of
the expected number of patients undergo genetic testing.
Identiﬁcation of a hereditary predisposition can be life-
saving. When more patients are traced with hereditary
colorectal cancer, an increasing number of relatives can
receive appropriate surveillance, which will prevent pre-
mature death from colorectal cancer [4]. To enhance the
detection of Lynch syndrome, a special strategy has been
developed for risk patients who cannot be recognized by
family history. This new strategy called MIPA involves
MSI-testing by pathologist in new patients with CRC
below the age of 50 [5]. It is being introduced at an
increasing number of hospitals. In this strategy, the
pathologists select patients and tumour specimens for
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DOI 10.1007/s10689-009-9239-7microsatellite instability (MSI) testing. In case of a
positive MSI test, the patient is at risk for Lynch syn-
drome and thus referred for genetic counseling to a
clinical genetic center.
For the patients, the difference between the new
strategy and the existing procedure is that genetic coun-
selling and testing is discussed very shortly after the
diagnosis of colorectal cancer, instead of a long period
after diagnosis and treatment. In this early stage after
diagnosis, patients with colorectal cancer may be more
emotionally vulnerable. Concurrently, these patients are
confronted with three major tasks: (1) to cope with their
cancer, (2) to cope with the consequences of a possible
genetic risk and (3) to consider informing and discussing
genetic counseling and DNA-testing with their blood
relatives. Extended work already has been accomplished
on familial cancer in general, including colorectal patients
tested for Lynch syndrome. In a number of reviews on
familial cancer, colorectal cancer was included as one of
the familial cancers [6, 7]. Many studies describe the
psychological impact of pre symptomatic testing for
Lynch syndrome [8–22]. From these studies it can be
concluded that in general genetic counselling and pre
symptomatic testing for Lynch syndrome can lead to
increased distress immediately after DNA-test disclosure
but does not lead to long-term adverse effects. Other
related studies assessed experiences of patients and family
members with genetic counselling for hereditary cancer
and [23], the impact of attendance of a familial colorectal
clinic on cancer-related concerns [24], subjective per-
ception regarding colorectal cancer [25, 26], compliance
with screening after testing [26], genetic testing for Lynch
syndrome in colorectal cancer survivors who were more
than 1 year after diagnosis [27] and quality of life after
various surgical procedures [28].
Obviously, this new Lynch detection strategy gave rise
to systematically survey relevant data related to the issue of
the impact of symptomatic genetic testing in patients with
colorectal cancer in their ﬁrst year after colorectal cancer
diagnosis. A literature review was conducted to identify the
psychological impact of colorectal cancer, focusing on the
impact of the malignancy during the ﬁrst year after primary
treatment and of the additional impact of genetic testing for
Lynch syndrome in affected patients.
Materials and methods
The electronic databases PubMed and PsychInfo were
searched to identify all the reports published between
January 1997 and October 2007 on the psychological
impact of colorectal cancer and genetic testing for hered-
itary colorectal cancer (Lynch syndrome) in patients during
their ﬁrst year of colorectal cancer. Two searches were
performed in each database.
Search 1 retrieved literature on the psychological impact
of the diagnosis and treatment of colorectal cancer. A
sensitive search strategy was adopted using the follow-
ing keywords: colorectal cancer, colorectal tumour(s),
colorectal carcinoma, colorectal neoplasms, psychologi-
cal distress, psychological adaptation, coping, emotional
adjustment, anxiety, depression and quality of life. Using
these keywords, 470 abstracts were retrieved: 415 from
PubMed and 55 from PsychInfo. After removing doubles,
one of the reviewers (KL) checked all the titles and
abstracts. Full text copies were obtained when the studies
had possible relevance. Inclusion criteria were (1) studies
on patients in their ﬁrst year with colorectal cancer (2)
psychological outcome measurements, (3) peer-reviewed
articles in English, French or Dutch. From studies with a
prospective design with long-term follow-up, only the
results up to 1 year were retrieved. Exclusion criteria were
(1) Patients with colorectal cancer aged[70 years. These
patients are not generally referred for genetic testing due to
their advanced age. (2) Colorectal cancer disease man-
agement studies and subjective experiences. (3) Qualitative
design. (4) Research into non-standard medical treatment.
(5) Publications of which no relevant data (mean scores)
could be retrieved. Based on these criteria, 17 studies
remained (see Fig. 1).
Search 2 retrieved literature on the psychological impact
of genetic testing in patients with colorectal cancer. The
keywords in search 1 were used in combination with the
terms genetic testing, genetic predisposition to disease,
genetic screening, genetic counseling and genetics. Using
these keywords, 101 abstracts were retrieved. After
removing doubles, one of the reviewers (KL) checked all
the titles and abstracts. Full text copies were obtained of all
the possibly relevant studies. Inclusion criteria were (1)
patients diagnosed with colorectal cancer (2) psychological
outcome measurement, (3) peer-reviewed articles in Eng-
lish, French or Dutch. Exclusion criteria were (1) Pre-
symptomatic/predictive testing, because our focus was on
the impact of genetic testing in patients diagnosed with
colorectal cancer. (2) Qualitative design. (3) Genetic test-
ing for Familial Adenomatous Polyposis (FAP). (4)
Publications of which no relevant data (mean scores) could
be retrieved. Based on these criteria, ten studies remained
(see Fig. 1).
Additional free text searches were performed in Pub-
Med, PsychInfo as well as in the Cochrane Library
database and in Embase using all the above-mentioned
keywords to select reviews on the psychological impact of
colorectal cancer and genetic testing for hereditary colo-
rectal cancer. However, none of these searches led to any
relevant publications.
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123Methodological quality
The studies were assessed according to the guidelines for
levels of evidence and grades of recommendation, supplied
by the Oxford-Centre for Evidence-based Medicine. A
level of evidence (LE) 1 refers to RCT studies, LE2 to
cohort studies, LE3 to case-control studies, LE 4 to case-
series and LE5 to expert opinions (http://www.cebm.net/
levels of_evidence.asp).
Results
I Psychological impact of colorectal cancer
Table 1 gives a summary of each of the 17 papers [29–45]
included in our review. The vast majority of the patients
with colorectal cancer were older than 50 years. As a result
of the heterogeneity of psychological variables and used
measurement instruments of the retrieved studies, a limit
was set in describing those studies that used the European
Organization for Research and Treatment in Cancer (EO-
RTC) QLQ-C30 scale. In ten out of the 17 studies, the
European Organization for Research and Treatment in
Cancer (EORTC) QLQ-C30 scale had been used to
measure the quality of life of the patients [29–32, 35, 41,
43–46]. This scale has frequently been used to assess
health-related quality of life in various groups of cancer
patients [47].
The mean scores on functional status were retrieved
from the studies, because an important aim of this review
was to evaluate functioning after treatment for colorectal
cancer. The scores are presented in Table 2. Our compar-
ison may not do justice to the special qualities of each
individual study, as their designs were intended to provide
answers to speciﬁc research questions, not to facilitate
comparability. Nevertheless the comparison adds new
dimensions to our knowledge in this area. To evaluate the
signiﬁcance of these function scores, they were compared
to reference data from a random sample (n = 2081) of the
general (non-cancer) adult population [47] and from breast
cancer patients [48] (Table 2). According to the MIPA
(MSI test by pathologist) procedure, MSI-positive patients
are usually informed about the results and offered genetic
testing within 3 months after surgery. Therefore, clear
distinction is made between psychological functioning in
the ﬁrst 3 months after treatment and in the subsequent
period up to 1 year after treatment. In the publications of
Schmidt [42] and Tsunoda [44] the EORTC-QLQ-C30 data
were presented in graph and mean data could not be
obtained and used reliably. The study of Wilson et al. [45],
only presented mean data on EORTC-QLQ-C30 Global
Health Status. Therefore, these three studies are not
reﬂected in Table 2.
Regarding the psychosocial impact of CRC with other
instruments than the EORTC-QLQ-C30, it appeared that
often different questionnaires were used, concerning
patients at different ages, with different types of colorectal
Abstracts identified by keywords  
(*1) n=470
After reading 
abstracts and 
removing doubles    
n= 415
> 1 year after CRC 
diagnosis  
 n= 18
Review  
n=8
Too specific medical 
treatment or patient 
group   
n=3
No psychological 
outcome 
measurements  
 n= 2 
Other non-relevant 
design n=7 
Included n=17 
 Abstracts identified by keywords 
   (*2) n=101  
After reading 
abstracts and 
removing doubles 
n= 74
Qualitative design 
n=3
Review 
n= 2
Presymptomatic   
testing n=7
Other non-relevant 
design n=5 
Included  n=10 
Fig. 1 Selection of studies on
the psychological impact of
colorectal cancer until 1 year
after treatment (*1) and
diagnostic genetic testing for
hereditary colorectal cancer (*2)
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123cancer and often with different times of data collection.
Still, an overall impression was obtained that demands of
illness, especially psychosocial and existential concerns,
were greater among the youngest age group below
45 years. Moreover, patients with a stoma showed higher
levels of depression and poorer social function than non-
stoma patients. Especially men with a stoma reported
sexual problems as did patients after treatment for rectal
cancer’’.
Impact of colorectal cancer on functional status
Up to 3 months after treatment
Table 2 shows that compared to the reference data, colo-
rectal cancer led to reduced social functioning (especially
in the patients with a stoma) as well as to decreased role
and physical functioning [29, 30, 32, 37, 41, 43]. Patients
of younger than 65 years and those with a stoma reported
reduced health-related quality of life 6 weeks after surgery
[45]. In the group with rectal cancer the men suffered from
more problems with their sexual functioning after
abdominoperineal resection than the women [43]. It can be
concluded that immediately after treatment for colorectal
cancer, physical, social and role functioning were dimin-
ished especially in patients with a stoma, compared to
levels of physical, social and role functioning of a selected
sample of adults [47] and of patients with lung cancer
(another common malignancy worldwide) [49, 50].
Between 3 and 12 months after treatment
Reduced role, emotional and social functioning continued
up to 1 year after treatment. The women reported poor
physical functioning [43] compared to the reference data
[47] and the scores from a severely fatigued breast cancer
group [48]. Global health status scores of the patients with
colorectal cancer were also poorer than the reference data
[47]. Severe limitations were found in emotional and social
functioning up to 1 year after treatment. These problems
were especially likely to affect patients of younger than
60 years [30]. In the men, strain due to sexual impairment
appeared to persist [29, 43, 46]; the men with a stoma had
more sexual problems than those without [41]. Rectal
cancer patients reported poor role and social functioning
compared to the reference data [47] up to 1 year after
treatment [32]. In the patients who had pre-operative
radiotherapy, emotional functioning was impaired com-
pared to the norm data [47]. At 12–16 months after
radiotherapy, these scores had returned to normal levels
[29]. Thus, severe problems with emotional and social
functioning persisted up to 1 year after treatment,
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123especially in the patients of younger than 60 years and in
those with a stoma.
Impact of colorectal cancer on demands of illness
and spiritual well-being
In two studies, patients younger than 45 years reported
greater demands of illness (hardships or stressors that
require coping or adjustment to illness) than the older
patients [33, 36]. Fernsler et al. [33] also showed that such
demands of illness were greater in men and in men and
women who had received treatment in the previous
2 months; in contrast, the women reported signiﬁcantly
higher spiritual well-being than the men. This leads to the
conclusion that colorectal cancer caused more hardships
and stressors in men and in patients diagnosed before the
age of 45 years.
II Psychological impact of genetic testing
for Lynch syndrome
Summaries of the ten relevant studies are shown in
Table 3. Nearly all the studies had gathered data on the
patients before disclosure of the genetic test result. Two
studies had made assessments pre-test and post-test
[16, 51], whereas one study had only made assessments
post-test [52]. Very few studies gave speciﬁc details about
the time interval since the diagnosis of colorectal cancer
and inclusion in the study [53, 54]. Table 3 also shows
the diversity in outcome measures and (self-administered)
questionnaires to gather data [16, 51, 55–58]. The aim of
this review was to determine how patients with colorectal
cancer reacted to (the offer of) genetic testing. Therefore,
the psychological reactions were documented according to
stage of genetic testing the patients had reached at the
time of the studies. The process of genetic counselling
was divided into three distinct stages: (1) Period of
genetic counselling and if desired, having a blood sample
taken. (2) Period of waiting for the result of the DNA
analysis. (3) Period after disclosure of the genetic test
result.
Psychological reactions before genetic counselling
The three relevant studies showed that patients with colo-
rectal cancer tended to have positive attitude towards
genetic testing [56, 57, 59]. Their most common motivation
to undergo genetic testing was concern about the risk of
colorectal cancer in close relatives. Motivation was the
highest in the younger patients, in those with early stage
disease and in those who had more frequent thoughts about
hereditary colorectal cancer [57]. In a group of patients
with colorectal cancer who attended an information session
about Lynch syndrome, 28% developed a clinically sig-
niﬁcant level of cancer-worry-related distress [56]. In
conclusion, motivation to undergo genetic testing was
primarily the need to know if close relatives were at
increased risk for colorectal cancer and was strongly
present in younger patients.
Psychological reactions before and
after genetic counseling
Other studies obtained data on the patients after patients
had consented to have a blood sample taken for DNA
analysis. Keller [55] and Murakami found clinically rel-
evant depression scores before and after genetic
counseling in 19 and 5% of the patients, respectively [51].
Another study reported clinically relevant anxiety levels
in 32% of the patients before genetic counseling, whereas
the scores dropped to 16% after genetic counseling [55].
In a group of patients who had given a blood sample for
genetic testing, the prevalence of depressive symptoms
was 24%, although all the scores remained within the
clinically normal range [54]. Patients in the age group of
younger than 50 years had higher levels of anxiety and
depression but the scores were within the normal range;
their data also showed signiﬁcant associations between
pre-test distress, a history of familial mortality from
colorectal cancer and anticipation of becoming depressed
post-test [53]. Characteristics associated with depression
were female sex, less formal education, fewer sources of
social contact; associations with anxiety were younger
age, less formal education, Non-Caucasian race, more
severe disease and fewer sources of social contact [54].
Intrusion scores reached clinically relevant levels in 14%
of the patients [55]. Higher intrusion and avoidance
scores were found in women and in the patients who had
been diagnosed with colorectal cancer less than 1 year
previously, although all the scores remained within the
normal clinical range [53]. Clinically relevant cancer-
worry-related distress was detected in 25% of the patients
before genetic counseling, but after genetic counseling,
this dropped to 13% [55]. In conclusion, most psycho-
logical distress scores remained within the normal range
before the result of the genetic test was disclosed,
although a minority of the patients developed clinically
relevant anxiety and depression levels. Vulnerable sub-
groups were female patients and male patients diagnosed
before the age of 50 years.
Psychological reactions after disclosure
of the genetic test result
Disclosure of the genetic test result led to signiﬁcant
depression scores in 7% of the patients and post-traumatic
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123stress symptoms in 5% [51]. Lynch syndrome mutation
carriers showed higher test-speciﬁc distress than non-car-
riers but these scores returned to baseline between 2 and
12 weeks after receiving the test result [16]. The only
predictor of psychological distress after disclosure of the
test result was a history of depression [51]. It can be con-
cluded that disclosure of the genetic test result did not lead
to any relevant levels of psychological distress in most
patients. Vulnerable subgroups seemed to be patients with
pre-test distress, high familial mortality from colorectal
cancer and a history of depression. Therefore, a subgroup
of vulnerable patients whose genetic test discloses Lynch
syndrome mutation carrier ship may beneﬁt from extra
psychological counselling.
Discussion
This literature review shows that little is known about the
additional psychological impact of obtaining a genetic test
disclosure in newly diagnosed patients with colorectal
cancer. Only ten studies were identiﬁed on diagnostic
genetic testing in colorectal patients. Most of these studies
measured distress prior to genetic test disclosure, but did
not obtain data after disclosure of the test result. Prior to
disclosure of the genetic test result, female patients and
men who were diagnosed with colorectal cancer before the
age of 50 years appeared to be more vulnerable to genetic-
test-related distress. A history of depression and high levels
of pre-test distress were strongly associated with genetic-
test-related distress and cancer related worries. It is gen-
erally known that a young age at diagnosis and multiple
family members with cancer are hallmarks of heredity.
Therefore, signiﬁcant levels of anticipated psychological
distress prior to disclosure of the genetic test result in
patients with a history of familial mortality from cancer
[53] can also be regarded as relevant to patients with
colorectal cancer who are suspected of Lynch syndrome
carriership.
The few studies available on distress after disclosure of
the genetic test result revealed ambiguous results. For
patients with different types of cancer, the impact of
genetic testing many years after the initial cancer diagnosis
and treatment was strongly inﬂuenced by their former
experience of cancer [7]. Dorval hypothesized that after
disclosure of the genetic test result, cancer patients may be
more aware of their own risk developing a second primary
tumour and be more conscious of the contribution of
genetics to an increased risk of cancer in their offspring
[60]. When genetic testing was offered to recently diag-
nosed colorectal cancer patients, the majority did not
object to an active approach [61]. Individuals at high-risk
for Lynch syndrome proved to know very little about
microsatellite instability (MSI) testing, a hallmark for
patients at risk for Lynch syndrome, but held positive
attitudes towards MSI test utility [62].
This literature review also shows that most patients with
colorectal cancer experience diminished physical, social
and role functioning during the ﬁrst 3 months after primary
treatment. Decreased emotional and social functioning
could persist for up to 1 year after treatment, especially in
patients of younger than 60 years and in those with a
stoma. Speciﬁc subgroups of patients with colorectal can-
cer appeared to be more vulnerable to genetic-testing-
related distress, but their actual levels of distress did not
generally reach clinical signiﬁcance. Reduced emotional
and social functioning may be related to the many taboos
that still surround bowel dysfunction [63]. Especially the
younger patients reported severe distress due to malad-
justment to their colorectal cancer. Having a stoma can
lead to feelings of stigmatisation and lead to withdrawal
from social activities [64, 65]. Recurring themes in patients
with colorectal cancer are loneliness and isolation [63]. It
might be expected that disabilities after colorectal cancer
treatment prevent the younger patients from going to work
and contribute to their impaired social and role functioning,
but it was found that most patients with colorectal cancer
returned to work after treatment [64, 66]. An additional
source of distress especially in younger male patients was
the possible impact on sexual functioning [64, 67]. Studies
have shown that after treatment for rectal cancer, sexual
problems were common, inadequately discussed and/or
treated by physicians [67]. Furthermore, the potential for
impotence due to treatment for colorectal cancer was a
serious concern especially in patients of younger than
60 years [64].
Conclusion
This review identiﬁes the psychological impact of colo-
rectal cancer during the ﬁrst year after treatment and
indicates speciﬁc subgroups of patients with colorectal
cancer who could be vulnerable for genetic-testing-related
distress. Most of the retrieved studies on diagnostic genetic
testing for Lynch syndrome exclusively measured distress
prior to genetic test disclosure and focused on patients who
were diagnosed with colorectal cancer several years ago.
Therefore, we are still unable to identify the psychological
impact of genetic testing for Lynch syndrome in recently
diagnosed patients with colorectal cancer.
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